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Abstract: This study aims to investigate alleles of the human apolipoprotein E (APOE) and of the angiotensin-con-
verting enzyme (ACE) genes as risk factors for poor quality of sleep in elderly individuals with no major cognitive de-
cline. This cross-sectional, analytical study was conducted with 163 participants aged 75 years in average and 85% 
female. Sociodemographic, anthropometric and clinical data were gathered, and sleep quality was assessed using 
the Pittsburgh Sleep Quality Index (PSQI) and the Epworth scale, with patient followed for years prior to these evalu-
ations to rule out onset of major mental disorders. Genotyping of classic polymorphic sites for the ApoE (rs429358 
and rs7412) and the ACE (rs4646994) genes used peripheral DNA. A total of 63% of the subjects reported poor 
quality of sleep assessed by the PSQI whereas 54 (33%) reported daytime sleepiness through the Epworth scale. A 
significant correlation was observed between APOE and PSQI, with a greater frequency of the poor nighttime sleep 
quality phenotype among ε2 carriers, whereas no correlation was found among any of the sleep scores and the ACE 
genotypes. Thus, we suggest a correlation between APOE alleles and scale-assessed sleep quality scores in older 
adults, with no implications for ACE alleles, in a context devoid of cognitive impairment.
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Introduction
Good quality sleep is important in sustaining 
the individual’s physical functioning and psychi-
atric well-being [1]. However, one third of the 
population is affected by sleep complaints, ren-
dering major social, medical, and/or economic 
impact to subjects, families and society [2]. 
Sleep problems in old age are prevalent and 
are known to associate with physical and psy-
chological factors. Survey revealed that over 
50% of all adults aged 55 to 84 years-old had 
sleep complaints such as trouble in falling 
asleep or waking up repeatedly at night [1].
Sleep is influenced by genetic and environmen-
tal factors [3]. Partinen et al. [4], found high 
estimates of heritability for sleep length and 
sleep quality in twin adults (h2 = 0.44). Also, the 
overall sleep pattern (total number of hours 
slept) of monozygotic twins living apart com-
pared to that of monozygotic twins living togeth-
er were found to be correlated (r = 0.53 and r = 
0.49, respectively), implying that genetic ele-
ments pose an important contribution to deter-
mine total sleep time [5].
Understanding the genetic basis of sleep disor-
ders is important because it leads to insights 
about its pathophysiology, and may lead to new 
diagnostic tests and more importantly to novel, 
personalized therapies for patients with sleep 
disorders [6]. Kadotani and colleagues found 
statistical association between the ε4 allele of 
the apolipoprotein E gene (APOE) and sleep 
apnea in a sample aged 32 to 68 years [7]. 
However, Foley and colleagues examined this 
association among Japanese-American men 
aged 79 to 97 years and, after adjusting for 
age, body mass index, smoking and use of anti-
hypertensive medications, found no associa-
tion between ε4 and apnea-hypopneia indexes 
greater than 15 (odds ratio [OR], 0.77; 95% con-
fidence interval [CI], 0.52-1.14) [8]. A polymor-
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phism in the angiotensin-converting enzyme 
was also reported to be associated with moder-
ate obstructive sleep apnea syndrome, espe-
cially in hypertensive patients [9].
APOE is located in chromosome 19, and pro-
duces different protein isoforms based on 
three existent polymorphic variants (ε2, ε3 and 
ε4). Their frequencies vary substantially around 
the world, with ε3 as the most common form in 
almost every population, being considered the 
‘wild-type’ allele [10]. The ε4 variant is the larg-
est known genetic risk factor for the late-onset, 
sporadic form of the Alzheimer disease [11] 
and is related with a worsened prognosis in 
patients with multiple sclerosis and Parkinson’s 
Disease [12].
Regarding the ACE gene, Rigat and others 
described its main variation, consisting of an 
insertion/deletion polymorphism encompass-
ing 287 base pairs within a noncoding region 
[13]. This alteration yields three genotypes (II, 
DD, ID), and the D allele is believed to produce 
60% higher activity of the enzyme in the serum 
[13, 14]. Evidence from several animal and 
human studies strongly supports involvement 
of this multi-enzyme system in the pathogene-
sis of vascular disorders. Subjects with the DD 
genotype had increased risk for myocardial 
infarction as well as for left ventricle hypertro-
phy, post-infarction remodeling, and idiopathic 
arterial hypertension [15]. Despite the over-
whelming amount of information regarding the 
contribution of the APOE and ACE genes to 
classic disorders as dementia and infarction, 
respectively, proper description of their associ-
ation with less common clinical traits remain 
elusive and should be addressed.
All in all, finding ways to minimize sleep disor-
ders in the elderly population has consistently 
been associated with improvement in quality of 
life, regardless of health status and biological 
background, and is an important public health 
action [16]. In this study, we aimed to investi-
gate the APOE and ACE alleles as genetic risk 
factors for poor quality of sleep in non-dement-
ed elderly individuals devoid of prior cognitive 
decline.
Materials and methods
Study design and patients
This was a cross-sectional, analytical study wi- 
th non-demented elderly individuals who att- 
ended from August 2015 to July 2016 to the 
cohort work know as Prognosis and Therapeu- 
tics in Geriatrics (ProTeGer) in Brasília, Brazil. 
The subjects were admitted at two general geri-
atric outpatient clinics in the Brazilian Federal 
District (The Geriatric Center of the University 
of Brasilia and the Geriatrics Service of Catholic 
University of Brasilia).
Medical records were initially used only as 
source of preliminary information and initial 
selection, with due consultations performed as 
described latter to assure eligibility. But at this 
initial admission, medical records were sought 
for a validated Brazilian Portuguese version of 
the Mini-Mental State Examination (MMSE), 
with cut-off scores set at 18 and 26 points for 
individuals with ≤ 7 years and ≥ 8 years of for-
mal education, respectively [17]. Inclusion cri-
teria were being aged 60 years or older and 
exhibiting no cognitive decline according to the 
MMSE. Exclusion criteria were medically regis-
tered sleep complaints or disorders associated 
with acute conditions (uncompensated illness-
es and recent psychiatric episodes), severe agi-
tation or unstable medication use (prescription 
changes within 8 weeks) between last visits.
Clinical procedures
Individuals were invited to participate in struc-
tured interviews to identify their sociodemo-
graphic and clinical characteristics. Data were 
collected on identity, age (years), gender (male/
female), level of schooling (years), body mass 
index (BMI, kg/m2), geriatric depression scale 
(EDG score), comorbidities (yes/no), and self-
reported health condition (excellent/very good/
good/bad/very bad), as well as on smoking 
(yes/no) and alcohol consumption (yes/no). 
Systemic arterial hypertension (SAH) presence 
(yes/no) was defined as repeatedly elevated 
blood pressure ≥ 140 (systolic) and/or ≥ 90 
(diastolic) mmHg while type-2 diabetes occur-
rence (yes/no) was defined by fasting glycated 
hemoglobin ≥ 6.5% and/or use of antidiabetic 
drugs, considering data from medical records. 
Current use of drug classes as hypnotics, anti-
depressants or other psychoactive agents that 
could interfere with sleep was also investigated 
and recorded (yes/no). During the interviews, 
disorders that could interfere with a partici-
pant’s overall state of health (e.g. cancer, epi-
lepsy, immobility, and stroke), such as impor-
tant sensory (visual and/or auditory) impair-
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ment, were identified by the clinical team and 
considered as further exclusion criteria.
Because all participants had been recruited for 
previous clinical and molecular studies [18], 
with patient’s admission in the geriatric servic-
es having occurred up to 2012, cognitively 
intact patients at baseline could be monitored 
to exclude the possibility of cognitive decline 
over time by means of subsequent evaluations. 
Therefore, clinical reassessments were per-
formed at least once for each patient between 
48 and 78 months after the initial cognitive 
evaluation on admission at the health center, 
with only patients showing no clinically impor-
tant decline during the period being enrolled for 
evaluations concerning their sleep profile. 
The instrument used for nighttime sleep ass- 
essment was the Pittsburgh Sleep Quality Index 
(PSQI), a clinically useful instrument to mea-
sure the quality and pattern of sleep in the 
older adult [19]. The PSQI global score is calcu-
lated by summing scores of seven subscales, 
resulting in a range from 0 to 21. A global sum 
of 5 or greater indicates a poor quality of sleep. 
On its turn, the Epworth scale (ESS) was used 
to assess daytime sleepiness [20]. Ranging 
from 0 to 24, global scores of 10 or higher indi-
cate daytime excessive somnolence. The appli-
cations of the questionnaires occurred individ-
ually during a regular clinical visit, being filled 
out with help of the researchers who explained 
the purpose of each question seeking to facili-
tate the patient’s understanding without inter-
fering with the answers.
This study was approved by the institutional 
ethics committee and conducted according to 
the Helsinki Declaration. Participation was vol-
untary, and written informed consent was 
obtained from each participant.
Genotyping procedures
The total genomic DNA of each participant was 
collected using routine laboratory procedures. 
Genotyping the common human APOE alleles 
were established according to a modified ver-
sion of a method developed elsewhere [21] to 
determine the rs429358 and rs7412 variations 
by means of a multiplexed polymerase chain-
reaction (PCR) using primers sense (5’-ATGCC- 
GATGACCTGCAGAATR-3’) and antisense (5’-CG- 
CGGACATGGAGGACGTTR-3’) designed so that 
the 3’-most base recognized either A or G cor-
responding to Arg or Cys at positions 112 or 
158, respectively. Genotypes were identified 
based on the patterns of 588 and 451 base 
pairs (bp) amplicons generated. On its turn, the 
insertion (I)/deletion (D) polymorphism of the 
human ACE gene (rs4646994) was determined 
by inspection of the electrophoretic profile of 
PCR products, as described elsewhere and per-
formed with modifications [22]. The 490 bp (I 
allele) and the 190 bp (D allele) products were 
amplified using primers sense (5’-CTGCAGA- 
CCACTCCCATCCTTTCT-3’) and antisense (5’-G- 
ATGTGGCCATCACATTCGTCAGAT-3’) flanking the 
polymorphic site. Confirmation of the DD geno-
types was run using specific oligonucleotides 
(5’-TGGGACCACAGCGCCCGCCACTAC-3’ and 5’- 
TCGCCAGCCCTCCCATGCCCATAA-3’) to amplify 
an internal segment (335 bp) of the insertion 
sequence.
Each reaction tube contained 100 ng of DNA, 
10 mmol/l of Tris-HCl pH 8.3, 75 mmol/l of KCl, 
3.5 mmol/l of MgCl2, 0,2 mmol/l of dNTPs, 20 
pmol of each primer, 0.5 µg of purified chicken 
albumin and 1 U of Taq DNA polymerase 
(Phoneutria®, Minas Gerais, Brasil) in a final 
volume of 25 μl. After 1 min of hot start at 80°C 
and an initial denaturation for 2 min at 94°C, 
the amplifications were done for 30 cycles of 
40 s at 94°C, 45 s at 64°C and 50 s at 72°C 
followed by a final 5 min extension at 72°C. 
Reactions were run to confirm the DD geno-
types of the ACE gene by amplifying a fragment 
of the insertion sequence. All PCR products 
were separated by electrophoresis on 2% aga-
rose gels containing ethidium bromide at 50 
μg/ml, visualized by using CCD camera (Vilber 
Lourmat®, Eberhardzell, Deutschland), and 
examined using the gel analysis software 
enclosed (Photo Capt 1D) with confirmation by 
visual inspection comparing to a 50-bp molecu-
lar mass marker.
Statistical analysis
Statistical analyses were performed using the 
Statistical Package for the Social Sciences 
Version 17 (SPSS). Chi square test with Fisher’s 
exact proportion and Spearman’s correlations 
were used to study a possible correlation bet- 
ween variables. A p value of < 0.05 was consid-
ered significant. A second analysis using a con-
trolled correlation test was performed inserting 
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interfering variables into the model in order to 
verify if the original association is maintained. 
Results
A total of 163 participants were included in this 
study, aged 75 years in average and 139 (85%) 
being female. Most volunteers reported school-
ing of 4 years and an overall good health condi-
tion (66%). Of all, 103 (63%) of the subjects 
genotypes (Table 3). Also, no relationship was 
found between the APOE or the ACE genotypes 
with the Epworth assessed scores or with other 
clinical and sociodemographic variables deter-
mined in the sample. Correlation tests between 
ApoE and PSQI controlling for MEEM and EDG 
were run, and the association remained in 
place (r = -0.213; P = 0.007). The same was 
made with ApoE and Epworth, controlling for 
Table 1. Anthropometric, clinical and metabolic variables 
of the sample (n = 163)
Variables Value
Sociodemographic characteristics
    Female, n (%) 139 (85.2)
    Age, years 75.3 ± 7.0
    BMI, kg.m-² 26.5 ± 4.7
    Schooling, years 4.3 ± 3.7
Clinical conditions, n (%)
    T2DM 30 (18.5)
    SAH 127 (78.4)
    Smoking 26 (15.9)
    Alcoholism 9 (5.5)
Medications, n (%)
    Tricyclic antidepressants 11 (6.8)
    Non-tricyclic antidepressants 54 (33.3)
    Anticonvulsant drugs 13 (8.0)
    Benzodiazepines 10 (6.1)
    Hypnotic drugs 10 (6.2)
Instrument, n (%)
    PSQI (poor sleep quality) 103 (63.1)
    Epworth (excessive diurnal somnolence) 54 (33.1)
    MMSE, points 24 ± 3.7
    Geriatric depression scale (score ≥ 6) 45 (27.5)
    Self-reported health condition
        Excellent/Very good/Good 12 (78.4)
        Bad/Very bad 35 (21.3)
Genotypes, n (%)
    ECA
        DD 52 (31.9)
        DI 85 (52.1)
        II 26 (15.9)
    APOE
        ε2 (ε2ε2, ε2ε3) 14 (8.5)
        ε3 (ε3ε3) 121 (74.2)
        ε4 (ε3ε4, ε4ε4) 28 (17.1)
Data are expressed as average ± standard deviation (SD) for continu-
ous parameters or absolute count (with relative frequencies in paren-
thesis) for categorical features. BMI = body mass index; T2DM = type 2 
diabetes mellitus; SAH = systemic arterial hypertension.
reported poor quality of sleep by means 
of the PSQI whereas 54 (33%) reported 
daytime sleepiness through the Epw- 
orth scale. Homozygotes for ε3 were 
74% of the sample (n = 121), and the 
genotypes were in perfect Hardy-We- 
inberg equilibrium (P > 0.05). Other 
baseline characteristics are reported in 
Table 1.
In descriptive terms purely, the sample 
was remarkably abundant of diabetic 
and hypertensive individuals, with only 
30 (18.4%) devoid of either of these 
entities, denoting high prevalence of 
metabolic disorders as expected from 
the elderly of a developing country. But 
qui-square analyses showed no fre-
quency variation of these conditions 
across genotypes. In line with a profile 
of multimorbidity, consumption of psy-
chotropic agents also was unneglect-
able, with users of any of these drugs 
accounting for nearly half (n = 78; 
47.8%) of our sample, and with one 
quarter (n = 20; 25.6%) of the users 
taking two or more active principles 
simultaneously. Again, analyses failed 
to reveal variation in consumption of 
these drugs across genotypic groups. 
Accordingly, neither the sociodemo-
graphic data (gender, age, schooling) 
nor the other self-reported or clinically 
assessed scores (depression, BMI, 
self-reported health, smoking or alco-
hol intake) deviated in frequency or 
mean values according to APOE or the 
ACE genotypes.
A significant correlation was observed 
between APOE and PSQI (Table 2), with 
a greater frequency of the poor night-
time sleep quality phenotype among ε2 
carriers, whereas no correlation was 
found among these scores and ACE 
APOE, sleep and older adults
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MEEM, and an association remained non-exis-
tent (r = -0.035; P = 0.661).
Discussion
The present study did identify a correlation 
between classic genotypes of APOE and poor 
sleep quality at nighttime in elderly individuals 
clinically identified as having preserved cogni-
tive functions.
Similarly to our report, Drogos et al. [16] con-
ducted a study that investigated the associa-
tion between sleep quality and the APOE gene 
in healthy older adults. Using in-home polis-
sonography and actigraphy (to produce objec-
tive parameters of sleep) and the PSQI (for sub-
jective evaluation), a significant relationship 
between the presence of the ε4 allele and 
objective sleep disturbances was found, but 
not with subjective sleep complaints. In our 
study, regardless of only subjective parameters 
being measured, the main risk factor for poor 
sleep quality relied on the APOE ε2 allele. This 
apparent inconsistency with the findings of 
Drogo and colleagues may derive from the fact 
that our study was conducted in a context 
devoid of cognitive decline, since our protocol 
excluded from analysis those that developed 
impairment over a long follow up. Another pos-
sible explanation relies on the weak relation-
ship between subjective complaints of sleep 
(including PSQI scores) and objective measures 
of sleep, with perception measured through 
questionnaires reflecting distinct dimensions 
of those mapped through actigraphy and poly-
somnography [23].
In the literature, some studies relate the ε4 
allele to the appearance of obstructive sleep 
apnea (OSA) in elderly patients and other respi-
ratory events during sleep [24, 25]. However, a 
larger body of evidence aiming at measuring 
sleep problems in elderly sample point out con-
trariwise, showing that ε4 carriers present 
lower levels of snoring and of sleep apnea com-
pared to non ε4 carriers. Uyrum & Balbay, for 
instance, studying a sample of 73 patients 
aged 51 years old in average found that the 
individuals with at least one APOE ε2 allele (ε2/
ε3, ε2/ε4), compared to the individuals with no 
APOE ε2 alleles (ε3/ε3, ε3/ε4), had a 9.37-fold 
greater OSA risk [26]. In another report, indi-
viduals with APOE2 alleles (ε2/ε3, ε2/ε4) com-
pared to the individuals with the ε3/ε3 geno-
type had a 10-fold greater OSA risk [10]. Lastly, 
Larkin et al. [27] reported a significant relation-
ship between APOE ε2 and increased risk of 
OSA (P = 0.039). One meta-analysis evaluated 
the association between the APOE alleles and 
the risk of OSA and the results revealed that 
APOE profiles did not contribute to the pheno-
type [10].
All in all, genetic epidemiological studies have 
shown inconsistent and often nonreproductible 
findings regarding the association between 
APOE ε2/ε3/ε4 alleles and OSA susceptibility 
[28], and no conclusive association has yet 
been demonstrated between the APOE gene 
and sleep disturbance, sleep short of breath/
awaking, sleep adequacy, or daytime somno-
lence [29]. A meta-analysis published by Thakre 
et al. [30] concluded that the hypothesis of a 
sound association between APOE alleles and 
Table 2. Distribution of subjects according to sleep profiles across genotypic groups of the ApoE gene, 





Epworth Excessive diurnal somnolence 5 (35.7) 41 (33.9) 8 (28.6) 0.845
PSQI Poor nighttime sleep quality 12 (85.7) 78 (64.5) 13 (46.4) 0.038
Data expressed as absolute count (and proportion, in parenthesis) within genotype. *Chi squared test.
Table 3. Distribution of subjects according to sleep profiles across genotypic groups of the ACE gene, 





Epworth Excessive diurnal somnolence 23 (44.2) 23 (27.1) 8 (30.8) 0.112
PSQI Poor nighttime sleep quality 32 (61.5) 52 (61.2) 19 (73.1) 0.522
Data expressed as absolute count and proportion within genotype (in parenthesis). *Chi squared test.
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obstructive sleep apnea cannot either be sus-
tained or ruled out based on literature pub-
lished so far.
One report associating the APOE genotype and 
the risk for coronary artery disease concluded 
that effects of this gene polymorphism are 
plastic, highly depend on environmental and 
coexisting factors to determine actual risks 
[31]. Our findings might reflect such plasticity, 
and a better understanding of the role of this 
common genetic variation in the sleep profile 
may permit the identification of subgroups that 
are at increased risk to the development of 
sleep-deprivation disorders, especially by com-
paring diverse scenarios as groups more or 
less likely to develop late-onset dementia [16]. 
It is important to emphasize that no correlation 
between ACE genotype and excessive diurnal 
somnolence or poor nighttime sleep quality 
was observed in our settings. In line, a meta-
analysis published by Lee et al. did not observe 
any correlation between ACE gene polymor-
phism and risk of OSAS development or dis-
ease severity, with no significant correlation 
between the presence of D allele and risk of 
OSA observed after stratification to ethnic ori-
gin or comorbidities, particularly arterial hyper-
tension [32]. 
In summary, it is possible to notice in the litera-
ture that a correlation between the genotypes 
of APOE and sleep disorders is cogitated. 
Nonetheless, the authors could not elaborate 
any satisfying explanation for the intriguing 
phenomena reported herein apart from a pos-
sible exacerbation in obstructive sleep apnea 
prevalence among ε2 carriers. Therefore, we 
are prone to interpret our finding as limited evi-
dence for a link that should be addressed with 
caution, and further investigated thoroughly. 
This study has limitations. One is that specific 
sleep disorders (as short total sleep time, night-
time awakenings and long latency) were not 
determined. Moreover, we did not perform a 
power calculation before starting the study, 
and the small sample size could be considered 
a shortcoming. Nonetheless, the authors un- 
derstand that the report poses a contribution 
to the literature by providing evidence in a con-
text devoid of major mental disorders, since 
patients were followed over time prior to the 
analyses so to allow exclusion of those with 
important cognitive decline or psychiatric con-
ditions. Moreover, clinical assessments took 
into account consumption of sleep-interfering 
psychoactive drugs, and since analyses failed 
to reveal unequal distribution of users/non-
users across genotypes, the authors do not 
believe that the associative results here 
observed were pharmaceutically influenced.
Conclusion
In this study, we found correlation between the 
ε2 allele of APOE and a poor quality of sleep in 
older adults, and no association of ACE alleles 
with any of the scale-assessed sleep scores in 
a context devoid of cognitive impairment.
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